{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:29:15Z","timestamp":1773304155986,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T00:00:00Z","timestamp":1744934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40123-025-01141-y","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:04:16Z","timestamp":1744974256000},"page":"1325-1335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration"],"prefix":"10.1007","volume":"14","author":[{"given":"Federico","family":"Beretta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Zucchiatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Sacconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Fantaguzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Lingardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-9581","authenticated-orcid":false,"given":"Giuseppe","family":"Querques","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"10153","key":"1141_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, et al. Age-related macular degeneration. Lancet. 2018;392(10153):1147\u201359.","journal-title":"Lancet"},{"issue":"9","key":"1141_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/bjophthalmol-2014-305702","volume":"98","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascu- lar age-related macular degeneration by the European society of retina specialists (EUR- ETINA). Br J Ophthalmol. 2014;98(9):1144\u201367.","journal-title":"Br J Ophthalmol"},{"issue":"12","key":"1141_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244183","volume":"15","author":"FG Holz","year":"2020","unstructured":"Holz FG, Minnella AM, Tuli R, et al. Ranibizumab treatment patterns in prior ranibizumab- treated neovascular age-related macular de- generation patients: real-world outcomes from the LUMINOUS study. PLoS ONE. 2020;15(12):e0244183.","journal-title":"PLoS ONE"},{"key":"1141_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12886-016-0207-3","volume":"16","author":"JJ Arnold","year":"2016","unstructured":"Arnold JJ, Markey CM, Kurstjens NP, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degen- eration: a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016;16:31.","journal-title":"BMC Ophthalmol"},{"issue":"2","key":"1141_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000513048","volume":"244","author":"R Tadayoni","year":"2021","unstructured":"Tadayoni R, Sararols L, Weissgerber G, et al. Brolucizumab: a newly developed anti-VEGF molecule for the treatment of neovascular age-related macular degeneration. Ophthalmologica. 2021;244(2):93\u2013101.","journal-title":"Ophthalmologica"},{"issue":"1","key":"1141_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","volume":"127","author":"PU Dugel","year":"2020","unstructured":"Dugel PU, Koh A, Ogura Y, et al. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolu- cizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72\u201384.","journal-title":"Ophthalmology"},{"issue":"5","key":"1141_CR7","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","volume":"13","author":"MA Zarbin","year":"2024","unstructured":"Zarbin MA, MacCumber MW, Karcher H, et al. Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae registry. Ophthalmol Ther. 2024;13(5):1357\u201368.","journal-title":"Ophthalmol Ther"},{"issue":"9","key":"1141_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.ophtha.2022.04.028","volume":"129","author":"AM Khanani","year":"2022","unstructured":"Khanani AM, Brown DM, Jaffe GJ, et al. MERLIN: phase 3a, multicenter, randomized, double- masked trial of brolucizumab in participants with nAMD and persistent retinal fluid. Ophthalmology. 2022;129(9):974\u201385.","journal-title":"Ophthalmology"},{"issue":"4","key":"1141_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00417-023-06329-1","volume":"262","author":"A Bilgic","year":"2024","unstructured":"Bilgic A, Kodjikian L, de Ribot FM, et al. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study. Graefes Arch Clin Exp Ophthalmol. 2024;262(4):1161\u20137.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"1141_CR10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, et al. Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology. 2020;127(5):616\u201336 (Erratum in: Ophthalmology. 2020 Oct;127(10):1434-1435).","journal-title":"Ophthalmology"},{"issue":"4","key":"1141_CR11","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ophtha.2017.09.028","volume":"125","author":"SR Sadda","year":"2018","unstructured":"Sadda SR, Guymer R, Holz FG, et al. Consensus definition for atrophy associated with age-related macular degeneration on OCT: classification of atrophy report 3. Ophthalmology. 2018;125(4):537\u201348 (Erratum in: Ophthalmology. 2019 Jan;126(1):177).","journal-title":"Ophthalmology"},{"issue":"5","key":"1141_CR12","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.survophthal.2023.03.004","volume":"68","author":"I Bachmeier","year":"2023","unstructured":"Bachmeier I, Armendariz BG, Yu S. Fibrosis in neovascular age-related macular degeneration: a review of definitions based on clinical imaging. Surv Ophthalmol. 2023;68(5):835\u201348 (Erratum in: Surv Ophthalmol. 2024 Nov-Dec;69(6):990).","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"1141_CR13","doi-asserted-by":"publisher","first-page":"3815","DOI":"10.1007\/s00417-024-06577-9","volume":"262","author":"H Yoshida","year":"2024","unstructured":"Yoshida H, Inoda S, Takahashi H, et al. Two-year outcomes of intravitreal brolucizumab for neovascular age-related macular degeneration: treat, extend, and stop-protocol. Graefes Arch Clin Exp Ophthalmol. 2024;262(12):3815\u201323.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"1141_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1159\/000530544","volume":"246","author":"M Cavalleri","year":"2023","unstructured":"Cavalleri M, Tombolini B, Sacconi R, et al. Real-life experience and predictors of visual outcomes with intravitreal brolucizumab switch for treatment of neovascular age-related macular degeneration. Ophthalmologica. 2023;246(2):158\u201368.","journal-title":"Ophthalmologica"},{"issue":"2","key":"1141_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/aos.15242","volume":"101","author":"CR Baumal","year":"2023","unstructured":"Baumal CR, S\u00f8rensen TL, Karcher H, et al. Efficacy and safety of brolucizumab in age-related macular degeneration: a systematic review of real-world studies. Acta Ophthalmol. 2023;101(2):123\u201339.","journal-title":"Acta Ophthalmol"},{"issue":"11","key":"1141_CR16","doi-asserted-by":"publisher","first-page":"1467160","DOI":"10.3389\/fmed.2024.1467160","volume":"15","author":"S Rossi","year":"2025","unstructured":"Rossi S, Gesualdo C, Marano E, et al. Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal brolucizumab. Front Med (Lausanne). 2025;15(11):1467160.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"1141_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12886-024-03706-0","volume":"24","author":"F Faraldi","year":"2024","unstructured":"Faraldi F, Lavia CA, Nassisi M, et al. Efficacy and safety of treat-and-extend intravitreal brolucizumab in naive and switched patients with macular neovascularization: one-year follow-up study. BMC Ophthalmol. 2024;24(1):436.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1141_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12886-024-03827-6","volume":"25","author":"N Hashiya","year":"2025","unstructured":"Hashiya N, Maruko I, Miyaguchi Y, Maruko R, Hasegawa T, Iida T. Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report. BMC Ophthalmol. 2025;25(1):42.","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"1141_CR19","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo ECO, Hatz K. Aflibercept high-dose (8mg) related intraocular inflammation (IOI)\u2014a case series. BMC Ophthalmol. 2024;24(1):520.","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"1141_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaophthalmol.2024.5889","volume":"143","author":"W Bruening","year":"2025","unstructured":"Bruening W, Kim S, Yeh S, Rishi P, Conrady CD. Inflammation and occlusive retinal vasculitis post faricimab. JAMA Ophthalmol. 2025;143(3):232\u20135.","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01141-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01141-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T13:08:10Z","timestamp":1747055290000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01141-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1141"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01141-y","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declare the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. Federico Beretta, Ilaria Zucchiatti, Federico Fantaguzzi, and Stefano Lingardo declare that they have no competing interests. Riccardo Sacconi is a consultant for\u00a0AbbVie, Bayer Shering-Pharma, Carl Zeiss Meditec,\u00a0Hoffmann-La-Roche, and\u00a0Novartis. Francesco Bandello is a consultant for\u00a0AbbVie,\u00a0Alcon, Alimera Sciences, Farmila-Thea, Bayer Shering-Pharma, Bausch and Lomb, Genentech, Hoffmann-La-Roche, NovagaliPharma, Novartis, Sanofi-Aventis, Thrombogenics, and Zeiss. Giuseppe Querques is a consultant for\u00a0AbbVie,\u00a0Alimera Sciences, Amgen, Heidelberg Engineering, KBH, LEH Pharma, Lumithera, Novartis, Bayer Shering-Pharma, Sandoz, Sifi, Soof-Fidia, and Zeiss. Giuseppe Querques and Riccardo Sacconi are Editorial Board members of Ophthalmology and Therapy. Giuseppe Querques and Riccardo Sacconi were not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This is a retrospective, observational, longitudinal investigation. This study adhered to the tenets of the Declaration of Helsinki (1964) and its later ammendments. Ethical approval was waived due to the retrospective nature of the study and because all of the procedures are part of routine clinical care. As no additional interventions were performed and all data were anonymized, informed consent was not required according to local regulations. No identifying information is included in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}